CLINICAL STAGE II HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Clinical trials for CLINICAL STAGE II HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE II HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE II HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Immunotherapy after standard treatment may keep HPV throat cancer at bay
Disease control OngoingThis study tests whether adding the immunotherapy drug nivolumab after standard chemoradiation helps people with HPV-positive throat cancer live longer without the cancer returning. About 636 adults with intermediate-risk, locally advanced disease will either receive nivolumab in…
Matched conditions: CLINICAL STAGE II HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:14 UTC
-
Could less radiation be just as good for some throat cancers?
Disease control OngoingThis study looks at whether a reduced dose of radiation therapy, combined with the immunotherapy drug nivolumab, can control early-stage HPV-positive throat cancer as well as the standard treatment of radiation plus cisplatin. The trial involves 384 non-smoking participants. The …
Matched conditions: CLINICAL STAGE II HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:13 UTC